You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms will combine real-life data sets in rare diseases with expertise in big data, artificial intelligence, and computational algorithms.
The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.
Molecular Health will make its analysis tools available to aid in the interpretation of raw data generated by customers of Agena's MassArray system.
The Workbench Manager helps labs manage their bioinformatics workflows while the Clinical Annotation software offers clinical variant interpretation services.
Molecular Health has renamed its portfolio ahead of planned product launches and an early-access program for its drug safety software starting in January.
The company will use the funds to continue building out its commercial platform and to drive product adoption.
Makers of NGS cancer profiling diagnostics lauded the preliminary proposal, but pointed out areas where the coverage criteria may miss patients who might benefit from testing.
The company's results add to a growing body of evidence, including from Foundation Medicine, that suggests such techniques have clinical utility for patients.
MolecularHealth announced that Fadi Braiteh has joined its advisory board. Braiteh is an oncologist with Comprehensive Cancer Centers of Nevada, specializing in gastro-intestinal, digestive system, and breast cancers.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.